Evidence map›Paper›PMID 36457321›Full record

ArticleFrontiers in public health2022

Sexualized drug use among men who have sex with men in Madrid and Barcelona: The gateway to new drug use?

Juan-Miguel Guerras, Juan Hoyos, Marta Donat, Luis de la Fuente, David Palma Díaz, Oskar Ayerdi, Jorge N García-Pérez, Patricia García de Olalla, María-José Belza

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Substance use in sexual minority youth: prevalence in an urban cohort.Child and adolescent psychiatry and mental health · 2023
    Article
  7. Chemsex and Psychosis: A Systematic Review.Behavioral sciences (Basel, Switzerland) · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Juan-Miguel GuerrasEscuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain.
Juan HoyosIndependent Researcher, Madrid, Spain.
Marta DonatEscuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain.
Luis de la FuenteCIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
David Palma DíazCIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Oskar AyerdiCentro Sanitario Sandoval, Instituto de Investigación Sanitaria San Carlos, Hospital Clínico San Carlos, Madrid, Spain.
Jorge N García-PérezUnidad de ITS de Vall d'Hebron-Drassanes, Hospital Vall d'Hebron, Barcelona, Spain.
Patricia García de OlallaCIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
María-José BelzaEscuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain.
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto de Salud Carlos III · ESAgència de Salut Pública de Catalunya · ESHospital de Sant Pau · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This original study compares the prevalences of drug use for any purpose and for sexualized drug use (SDU) among MSM. It also describes relevant characteristics of first SDU, analyzes to what extent SDU has been the first experience (the gateway) with different drugs by age and explores the correlates of SDU. Study participants included 2,919 HIV-negative MSM attending four HIV/STI diagnosis services in Madrid and Barcelona. They answered an online, self-administered questionnaire. Poisson regression models with robust variance were used. About 81.4% had ever used any drug, and 71.9% had done so in the last-12-months, while 56% had ever engaged in SDU, and 50% had done so in the last-12-months. Participants under 25 years old had the lowest prevalences of SDU, and the 25-39 age group the highest, except for Viagra, which was higher among those over age 40. The most frequently used drugs for first SDU were poppers (53.6%), cannabis (19.6%) and Viagra (12.2%). These drugs were also the most ever consumed for SDU. Among sexualized users, methamphetamine (78.3%) and Mephedrone (75.4%) were used always/most of the times for sex in the last-12-months. Around 72.2% of Mephedrone sexualized users and 69.6% of Methamphetamine vs 23.1% of ecstasy users' first consumption of these drugs involved use for sex. These drugs were provided to them free where they have sex for 66.8, 79.1, and 31.9%, respectively. On that occasion, 8.1% of Mephedrone, 6.8% of Methamphetamine and 18.4% of ecstasy users had sex only with steady partner; with 50.2, 56.2, and 26.2% respectively using a condom with any partner. SDU in the first use was associated with similar variables for recreational and chemsex drugs. The highest prevalence ratios were for having ever been penetrated by >20 men and having ever injected drugs. It can be concluded that the prevalence of SDU was more than half of the prevalence for any purpose. Thus SDU was the gateway to use for many drugs in an important proportion of users, who frequently consumed drugs that were free and had condomless anal sex with occasional and multiple partners. These circumstances were much more common for chemsex than for recreational drugs.

Indexed as

HIV InfectionsMethamphetamineN-Methyl-3,4-methylenedioxyamphetamineSexual and Gender MinoritiesSexually Transmitted DiseasesSubstance-Related DisordersAdultChild, PreschoolHomosexuality, MaleHumansMaleSildenafil CitratemephedroneMethamphetamineN-Methyl-3,4-methylenedioxyamphetamineSildenafil Citratechemsexdrug initiationdrug usemen who have sex with mensexualized drug use

Identifiers

PMID36457321
PMCPMC9705339
OpenAlexW4309214661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.